Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5489-5494

  Alagozlu, Hakan ^a   Ozdemir, Oztürk ^b   Koksal, Binnur ^a   Yilmaz, Abdulkerim ^a   Coskun, Mahmut ^b  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

Author keywords

HBV; HCC risk; Long term treatment; Polymerase gene mutation; YMDD

Indexed keywords

ADEFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; ASPARTIC ACID; DNA DIRECTED DNA POLYMERASE; DRUG DERIVATIVE; LAMIVUDINE; METHIONINE; PHOSPHONIC ACID DERIVATIVE; TYROSINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; FEMALE; FOLLOW UP; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN MOTIF; RETROSPECTIVE STUDY; TURKEY (REPUBLIC); VIROLOGY;

ADENINE; ADULT; AGED; AMINO ACID MOTIFS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; ASPARTIC ACID; CASE-CONTROL STUDIES; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; METHIONINE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; PROGNOSIS; RETROSPECTIVE STUDIES; TURKEY; TYROSINE;

EID: 84887572213     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5489     Document Type: Article

References (47)

1. Agca H, Sayiner AA, Sengönül A et al., (2011). A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations. Mikrobiyol Bul, 45, 664-76.
2. Allen MI, Deslauriers M, Andrews CW, et al (1998). Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology, 27, 1670-7.
3. Angus P, Vaughan R, Xiong S, et al (2003). Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology, 125, 292-7.
4. Aspinall EJ, Hawkins G, Fraser A, et al (2011). Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Lond), 61, 531-40.
5. Balzarini J, Wedgwood O, Kruining J, et al (1996). Anti-HIV and anti-HBV activity and resistance profile of 3TC and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun, 2, 363-9.
6. Bartholomeusz A, Locarnini SA (2006). Antiviral drug resistance: clinical consequences consequences and molecular aspects. Semin Liver Dis, 26, 162-70.
7. Baumert TF, Rogers SA, Hasegawa K, Liang TJ (1996). Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest, 98, 2268-76.
8. Carman WF, Trautwein C, van Deursen FJ, et al (1996). Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis.Hepatology, 24, 489.
9. Chen Y, Wang L, Xu H, et al (2013). Exome capture sequencing reveals new insights into hepatitis B virus-induced hepatocellular carcinoma at the early stage of tumorigenesis. Oncol Rep, 30, 1906-12.
10. Chen YM, Wu SH, Qiu CN, et al (2013). Hepatitis B virus subgenotype C2-and B2-associated mutation patterns may be responsible for liver cirrhosis and hepatocellular carcinoma, respectively. Braz J Med Biol Res, 46, 614-22.
11. Fontana RJ, Keeffe EB, Carey W, et al (2002). Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl, 8, 433-9.
12. Fung SK, Chae HB, Fontana RJ, et al (2006). Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol, 44, 283-90.
13. Gaillard RK, Barnard J, Lopez V, et al (2002). Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob Agents Chemother, 46, 1005-13.
14. Ganem D, Prince AM (2004). Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med, 350, 1118-29.
15. Gao C, Fang L, Zhao HC, et al (2013). Potential role of diabetes mellitus in the progression of cirrhosis to hepatocellular carcinoma: a cross-sectional case-control study from Chinese patients with HBV infection. Hepatobiliary Pancreat Dis Int, 12, 385-93.
16. Geramizadeh B, Nikeghbalian S, Kazemi K, et al (2013).Hepatocellular carcinoma in explanted livers of patients with genotype d HBV cirrhosis: report of the first experience from Iran. Arch Iran Med, 16, 348-50.
17. Guerrieri F, Belloni L, Pediconi N, Levrero M (2013). Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis, 33, 147-56.
18. Gwak GY, Lee CY, Lee DH, et al (2011). Clinical impact of the development of YMDD mutants in hepatitis B virus-associated glomerulonephritis. Hepatogastroenterology, 58, 1291-5.
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al (2006). Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis b for up to 5 years. Gastroenterology, 131, 1743-51.
20. Johnson MS, McClure MA, Feng DF, et al (1986). Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc Natl Acad Sci USA, 83, 7648-52.
21. Kim HJ, Park JH, Park DI, et al (2012). The influence of YMDD mutation patterns on clinical outcomes in patients with adefovir add-on lamivudine combination treatment. Liver Int, 32, 303-10.
22. Kohlstaedt LA, Wang J, Friedman JM, et al (1992). Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-90.
23. Lai CL, Chien RN, Leung NW, et al (1998). A one year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med, 339, 61-8.
24. Lavarone M, Colombo M (2013). HBV infection and hepatocellular carcinoma. Clin Liver Dis, 17, 375-97.
25. Lee CZ, Lee HS, Huang GT, et al (2006). Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol, 12, 5301-5.
26. Lee SH, Kim HS, Byun IS, et al (2012). Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. J Med Virol, 84, 217-22.
27. Lee YS, Suh DJ, Lim YS, et al (2006). Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 43, 1385-91.
28. Li D, Cheng H, Gong W, et al (2013). Detection of primary YMDD mutations in HBV-related hepatocellular carcinoma using hybridization-fluorescence polarization. J Virol Methods, 187, 259-63.
29. Lin CL, Kao JH (2008). Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci, 15, 137-45.
30. Liu K, Hou W, Zumbika E, Ni Q (2005). Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ Science B, 6, 1182-8.
31. Markowitz JS, Martin P, Conrad AJ, et al (1998). Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatolog, 28, 585-9.
32. Matsuda M, Suzuki F, Suzuki Y, et al (2004). YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine. J Med Virol, 74, 361-6.
33. Mello FC, Lago BV, Lewis-Ximenez LL, et al (2012). Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol, 12, 96.
34. Ogata N, Fujii K, Takigawa S, et al (1999). Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol, 59, 270-6.
35. Poch O, Sauvaget I, Delarue M, Tordo N (1989). Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J, 8, 3867-74.
36. Sarma MP, Asim M, Medhi S, et al (2012). Viral genotypes and associated risk factors of hepatocellular carcinoma in India. Cancer Biol Med, 9, 172-81.
37. Sato S, Suzuki K, Akahane Y, et al (1995). Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med, 122, 241-8.
38. Schildgen O, Sirma H, Funk A, et al (2006). Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med, 354, 1807-12.
39. Schildgen V, Ziegler S, Tillmann RL, Schildgen O (2010). Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance-a scholarly case. Virol J, 7, 167.
40. Singh S, Singh PP, Roberts LR, Sanchez W (2013). Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol, [Epub ahead of print].
41. Tan YW, Ge GH, Zhao W, et al (2012). YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study. Braz J Infect Dis, 16, 250-5.
42. Vassiliadis T, Nikolaidis N, Giouleme O, et al (2005). Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther, 21, 531-7.
43. Villamil FG (2002). Hepatitis B progress in the last 15 years. Liver Transpl, 8, 59-66.
44. Wang LL, Yu XJ, Dong QJ, et al (2012). HBV genotypes distribution and YMDD spontaneous mutation in Qingdao population. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 26, 250-2.
45. Wu F, Wu MJ, Zhuge XL et al (2012). Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Hepatobiliary Pancreat Dis Int, 11, 172-6.
46. Yang JH, Zhang H, Chen XB, et al (2013). Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations. World J Gastroenterol, 19, 3861-5.
47. Zhao J, Guo Y, Yan Z, et al (2012). The natural YMDD mutations of hepatitis B virus in Western China. Scand J Infect Dis, 44, 44-7.